Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Oct;24(4):551–553. doi: 10.1111/j.1365-2125.1987.tb03211.x

Effects of antacids and food on absorption of famotidine.

J H Lin 1, A N Chremos 1, S M Kanovsky 1, S Schwartz 1, K C Yeh 1, J Kann 1
PMCID: PMC1386320  PMID: 2891370

Abstract

The effect of a high potency antacid and food on the bioavailability of famotidine was studied in 17 healthy volunteers in an open randomized three-way cross-over trial. After an overnight fast, famotidine was administered to each subject as follows: 40 mg famotidine orally alone; 40 mg orally with antacid; and 40 mg orally with a standard breakfast. Coadministration of the antacid caused a small but significant reduction in the maximum plasma concentration (Cmax) of famotidine from 81.1 +/- 54.2 to 60.8 +/- 21.6 ng ml-1 (P less than 0.05) and a small decrease in the area under plasma concentration-time curve [AUC] from 443.3 +/- 249.2 to 355.0 +/- 125.1 ng ml-1 h (P greater than 0.05). However, there was only a minimal effect of food on these parameters; the Cmax and [AUC] were 81.6 +/- 29.6 ng ml-1 and 434.8 +/- 145.9 ng ml-1 h, respectively.

Full text

PDF
551

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gugler R., Brand M., Somogyi A. Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol. 1981;20(3):225–228. doi: 10.1007/BF00544602. [DOI] [PubMed] [Google Scholar]
  2. Kwan K. C., Till A. E. Novel method for bioavailability assessment. J Pharm Sci. 1973 Sep;62(9):1494–1497. doi: 10.1002/jps.2600620923. [DOI] [PubMed] [Google Scholar]
  3. Lin J. H., Los L. E., Ulm E. H., Duggan D. E. Urinary excretion kinetics of famotidine in rats. Drug Metab Dispos. 1987 Mar-Apr;15(2):212–216. [PubMed] [Google Scholar]
  4. Mihaly G. W., Marino A. T., Webster L. K., Jones D. B., Louis W. J., Smallwood R. A. High dose of antacid (Mylanta II) reduces bioavailability of ranitidine. Br Med J (Clin Res Ed) 1982 Oct 9;285(6347):998–999. doi: 10.1136/bmj.285.6347.998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Pendleton R. G., Torchiana M. L., Chung C., Cook P., Wiese S., Clineschmidt B. V. Studies on MK-208 (YM-11170) a new, slowly dissociable H2-receptor antagonist. Arch Int Pharmacodyn Ther. 1983 Nov;266(1):4–16. [PubMed] [Google Scholar]
  6. Vincek W. C., Constanzer M. L., Hessey G. A., 2nd, Bayne W. F. Analytical method for the quantification of famotidine, an H2-receptor blocker, in plasma and urine. J Chromatogr. 1985 Mar 22;338(2):438–443. doi: 10.1016/0378-4347(85)80118-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES